CHDI Foundation and Genzyme enter agreement to develop novel virally delivered gene-silencing therapeutic for Huntington’s disease

New York, NY, February 21 2014 – CHDI Foundation, Inc. and Genzyme Corporation have entered into a collaboration to develop adeno-associated virus delivery of a novel gene silencing therapeutic approach for Huntington’s disease. The agreed research plan encompasses the development of a therapeutic clinical candidate that will aim to lower …

Continue reading